Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Pain
Interventions: Baclofen 10mg, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Vascular Inflammation, ASCVD, ASCVD Management
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: eszopiclone, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Actinic Keratosis
Interventions: imiquimod cream, placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Saint Petersberg, Florida + 11 more

Conditions: Hepatorenal Syndrome, Acute Kidney Injury
Interventions: R2R01, Terlipressin; Drug
Lead sponsor: River 2 Renal Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Osteoarthritis of the Knee
Interventions: Infliximab, Placebo, Standard of Care: Methylprednisolone acetate; Drug
Lead sponsor: Herbert Lindsley, MD; Other
Eligibility: 35 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Raynaud, Scleroderma
Interventions: Fasudil; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-1-infection, Alcohol Drinking
Interventions: Alcohol, ethyl, moderate dose, Placebo; Other
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Alopecia Areata
Interventions: Deuruxolitinib, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 44 more

Conditions: Normal, PCOS
Interventions: oral micronized progesterone suspension, Placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Urinary Tract Infections
Interventions: LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX; Drug
Lead sponsor: Locus Biosciences; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Fresno, California • Lancaster, California • Los Angeles, California + 13 more

Conditions: Chronic Low-back Pain
Interventions: LY3526318, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 29
States / cities: Chandler, Arizona • Glendale, Arizona • Tempe, Arizona + 24 more

Conditions: Lymphoma
Interventions: Ibrutinib, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 44
States / cities: Tucson, Arizona • Greenbrae, California • La Jolla, California + 41 more

Conditions: Stuttering, Adult
Interventions: Aripiprazole 10 MG, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Posttraumatic Stress Disorder, Chronic Pain
Interventions: Stellate Ganglion Block Treatment, Placebo; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia
Interventions: PROCRIT, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • Santa Barbara, California + 18 more

Conditions: ADHD
Interventions: SPD503-AM, SPD503-PM, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 61
States / cities: Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more

Conditions: Type 2 Diabetes Mellitus
Interventions: XOMA 052, Placebo; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 67
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 64 more

Conditions: Complex Regional Pain Syndrome Type I
Interventions: Neridronate, Placebo; Drug
Lead sponsor: Ambros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 32 more

Conditions: Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, mRNA-1405, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more

Conditions: Methamphetamine Addiction
Interventions: GVG, placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: Nitric Oxide 160 ppm; Drug
Lead sponsor: Novoteris, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: LY3857210, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 28
States / cities: Chandler, Arizona • Phoenix, Arizona • Riverside, California + 23 more

Search by objective public record fields.

Baclofen as a Perioperative Analgesic Adjuvant

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Determining How Quickly Progesterone Slows LH Pulse Frequency

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Dopamine and Sensorimotor Function in Stuttering

Enhancing Cognitive Processing Therapy for Posttraumatic Stress Disorder Via Stellate Ganglion Block Treatment: A Pilot Trial

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Efficacy and Safety of SPD503 in Combination With Psychostimulants

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Assessment of GVG for the Treatment of Methamphetamine Dependence

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).